Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
3 hedge funds and large institutions have $53.3K invested in Achilles Therapeutics in 2026 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
582% more capital invested
Capital invested by funds: $7.82K → $53.3K (+$45.5K)
50% more funds holding
Funds holding: 2 → 3 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TC
Trium Capital
London,
United Kingdom
|
+$45.5K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TC
1
Trium Capital
London,
United Kingdom
| $45.5K | +$45.5K | +30,753 | New |
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $6.63K | – | – | – |
|
|
GI
3
GAMMA Investing
Foster City,
California
| $1.19K | – | – | – |
|
ACHL Hedge Fund Activity: Q1 2026 in Review
3 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q1 2026, worth a combined $53.3K — up 582% from $7.82K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ACHL positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Trium Capital, opening a new position worth an estimated $45.5K.
- 3 institutional investors held Achilles Therapeutics (ACHL) as of Q1 2026, up from 2 in Q4 2025.
- Funds reported $53.3K of Achilles Therapeutics stock for Q1 2026, up 582% quarter-over-quarter.
- 1 fund opened new Achilles Therapeutics positions in Q1 2026 and 0 closed out, a net change of +1 holder.
- The largest Achilles Therapeutics buyer in Q1 2026 was Trium Capital, an estimated $45.5K added.
Based on aggregated 13F filings for Q1 2026.